.
MergerLinks Header Logo

Announced

Sanofi to acquire Kadmon for $1.9bn.

Financials

Edit Data
Transaction Value£1,375m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium79%
One Off Charge-

Tags

Edit

Majority

Biotechnology

Friendly

United States

Pending

biopharmaceutical company

Acquisition

Single Bidder

Cross Border

therapies

Public

Synopsis

Edit

Sanofi, a French multinational pharmaceutical company, agreed to acquire Kadmon, a biopharmaceutical company, for $1.9bn. "We are excited that Sanofi has acknowledged the value of Rezurock and the deep potential of our pipeline. By leveraging Sanofi’s global resources and long-standing expertise in developing and commercializing innovative medicines, Rezurock is now well positioned for global accessibility, faster. I want to thank the entire Kadmon team, including management and the Board of Directors, and the Sanofi organization, for their ongoing commitment to patients and their caregivers," Harlan Waksal, Kadmon President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US